Results 151 to 160 of about 24,165 (274)

A translational multimodal machine‐learning prototype predicting valproate response in epilepsy treatment

open access: yesEpilepsia, EarlyView.
Abstract Objective Epilepsy affects ~1% of the global population and often requires lifelong antiseizure medication (ASM) therapy. Valproic acid (VPA) is a commonly prescribed first‐line ASM, yet only approximately half of patients achieve sustained seizure freedom. Treatment selection remains largely empirical.
Simeon Platte   +15 more
wiley   +1 more source

Gut‐microbiota‐brain Axis and post‐traumatic epilepsy

open access: yesEpilepsia Open, EarlyView.
Abstract There has been growing evidence that perturbations in gut‐microbiota‐brain axis (GMBA) are involved in mechanisms of chronic sequelae of traumatic brain injury (TBI). This review discusses the connection between GMBA and post‐traumatic epilepsy (PTE), the latter being a common outcome of TBI.
Andrey Mazarati
wiley   +1 more source

Epilepsy syndromes classification

open access: yesEpilepsia Open, EarlyView.
Abstract Epilepsy syndromes are distinct electroclinical entities which have been recently defined by the International League Against Epilepsy Nosology and Definitions Task Force. Each syndrome is associated with “a characteristic cluster of clinical and EEG features, often supported by specific etiologic findings”.
Elaine C. Wirrell   +4 more
wiley   +1 more source

Ketogenic diet for infantile epileptic spasms

open access: yesEpilepsia Open, EarlyView.
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury   +3 more
wiley   +1 more source

Real‐world effectiveness of highly purified cannabidiol in epilepsy associated with 15q11.2‐q13.1 duplication and deletion syndromes: A multicenter study

open access: yesEpilepsia Open, EarlyView.
Abstract This multicenter retrospective study evaluated the effectiveness and safety of highly purified cannabidiol (CBD) in 22 patients with 15q11.2‐q13.1 duplication or deletion syndromes (15q‐DDS), including 12 with 15q duplication syndrome (dup15q) and 10 with Angelman syndrome (AS). Median (interquartile range [IQR]) age at CBD initiation was 14.5
Emanuele Cerulli Irelli   +14 more
wiley   +1 more source

Artificial intelligence in the assessment of epilepsy‐related genetic mutations: Learned from GABAA receptors and GABA transporter 1

open access: yesEpilepsia Open, EarlyView.
Abstract This review examines how recent genetic and technological advances have transformed our understanding and treatment of genetic epilepsies (GEs), with a focus on disorders involving GABAA receptors (GABRs) and the GABA transporter 1 (GAT‐1) encoded by SLC6A1.
Juexin Wang, Jing‐Qiong Kang
wiley   +1 more source

Motivating paternal empathy and egalitarian attitudes to prevent maternal postpartum depressive symptoms: A randomized controlled trial

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To evaluate the effectiveness of a motivation‐based intervention for fathers to enhance empathy and egalitarian gender‐role attitudes, aiming to prevent maternal postpartum depressive symptoms. Methods This was a single‐blind, parallel‐group randomized controlled trial conducted at a regional hospital in Japan.
Shuhei Terada   +6 more
wiley   +1 more source

Tactile hypo‐responsivity in autism: Examining potential for diagnostic relevance

open access: yesJCPP Advances, EarlyView.
The study reported in this paper examined the utility of a brief tactile reactivity assessment in differentiating autistic children from those with other neurodevelopmental concerns and the association between tactile responsivity, autism symptomatology, developmental level, and adaptive skills.
Girija Kadlaskar   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy